nexalin.com (NXL): Debts to Book Capitalization

Nexalin Technology, Inc. (NXL) is developing high-tech non-invasive brain stimulation systems for depression therapy, focusing on the clinical validation of its developments. The ratio of debt to balance sheet capital demonstrates current financial stability, with the indicator value standing at 0.00. Business revenues are based on the sale and lease of equipment, while supply stability is ensured by specialized medical logistics.

This ratio is calculated as total debt relative to the book value of equity, providing a real-time assessment of changes in debt load. The metric allows for an evaluation of financial stability and the alignment of the liability structure with industry standards. For Nexalin Technology, Inc. (NXL), which develops non-invasive brain stimulation, this is a critical indicator of the balance between growth investments and credit pressure. The historical trend of debt levels relative to capitalization clearly demonstrates debt service risks.